This is supported by a DNA methylation analysis, which revealed a number of genes, among them MLH1, that were hypermethylated in a human ovarian cancer cell line model of cisplatin resistance, suggesting the utilization of these genes as clinically relevant biomarkers [62]. This evidence concerns the gene MLH1 and ovarian carcinoma.